<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Anti-VEGF Injection IOP Elevations - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVPwRTfA1NttscBT3SB1QAAAAY","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Anti-VEGF_Injection_IOP_Elevations","wgTitle":"Anti-VEGF Injection IOP Elevations","wgCurRevisionId":83217,"wgRevisionId":83217,"wgArticleId":13273,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Anti-VEGF_Injection_IOP_Elevations","wgRelevantArticleId":13273,"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],
"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},
"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Anti-VEGF agents have been employed for a variety of uses in the treatment of ocular disease, and several reports have shown both acute and chronic increases in intraocular pressure (IOP) following injection of these drugs. This article will review these data and their relevance to glaucoma."/>
<meta name="date" content="2022-07-23"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Anti-VEGF Injection IOP Elevations" href="/w/index.php?title=Special:ExportRDF/Anti-VEGF_Injection_IOP_Elevations&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Anti-VEGF_Injection_IOP_Elevations rootpage-Anti-VEGF_Injection_IOP_Elevations layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Anti-VEGF+Injection+IOP+Elevations" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Anti-VEGF+Injection+IOP+Elevations" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpxjvhirq"></button>
					<div class="collapse navbar-collapse hbpxjvhirq" id="hbpxjvhirq">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Anti-VEGF_Injection_IOP_Elevations" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk" class="new"><a href="/w/index.php?title=Talk:Anti-VEGF_Injection_IOP_Elevations&amp;action=edit&amp;redlink=1" rel="discussion" title="Discussion about the content page (page does not exist) [t]" accesskey="t" class="new ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Anti-VEGF_Injection_IOP_Elevations#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Anti-VEGF Injection IOP Elevations</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Ari.Stoner" title="User:Ari.Stoner">Ari M Stoner</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:John.lind" title="User:John.lind">John T. Lind, MD, MS</a>,&#160;<a href="/User:Zafar.Gill" title="User:Zafar.Gill">Zafar Gill, MD</a>,&#160;<a href="/User:Leonard.K.Seibold" title="User:Leonard.K.Seibold">Leonard K. Seibold, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Leonard.K.Seibold" title="User:Leonard.K.Seibold">Leonard K. Seibold, MD</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Update Pending</b>
</div>
</div>&#160;by <a href="/User:Leonard.K.Seibold" title="User:Leonard.K.Seibold">Leonard K. Seibold, MD</a> on July 24, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#History"><span class="tocnumber">2</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-3"><a href="#Post-injection_spike_in_IOP"><span class="tocnumber">3</span> <span class="toctext">Post-injection spike in IOP</span></a></li>
<li class="toclevel-1 tocsection-4"><a href="#Long-term_sustained_IOP_elevation"><span class="tocnumber">4</span> <span class="toctext">Long-term sustained IOP elevation</span></a></li>
<li class="toclevel-1 tocsection-5"><a href="#Development_of_Open-Angle_Glaucoma"><span class="tocnumber">5</span> <span class="toctext">Development of Open-Angle Glaucoma</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#Development_of_Angle-Closure_Glaucoma"><span class="tocnumber">6</span> <span class="toctext">Development of Angle-Closure Glaucoma</span></a></li>
<li class="toclevel-1 tocsection-7"><a href="#Exacerbation_of_Glaucoma"><span class="tocnumber">7</span> <span class="toctext">Exacerbation of Glaucoma</span></a></li>
<li class="toclevel-1 tocsection-8"><a href="#Post-Injection_Changes_to_Retinal_Nerve_Fiber_Layer"><span class="tocnumber">8</span> <span class="toctext">Post-Injection Changes to Retinal Nerve Fiber Layer</span></a></li>
<li class="toclevel-1 tocsection-9"><a href="#Proposed_Mechanism_for_sustained_IOP_increase_following_anti-VEGF_Injection"><span class="tocnumber">9</span> <span class="toctext">Proposed Mechanism for sustained IOP increase following anti-VEGF Injection</span></a></li>
<li class="toclevel-1 tocsection-10"><a href="#Management_and_Prevention"><span class="tocnumber">10</span> <span class="toctext">Management and Prevention</span></a></li>
<li class="toclevel-1 tocsection-11"><a href="#References"><span class="tocnumber">11</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Introduction">Introduction</span></h1>
<p>Anti-VEGF agents have been employed for a variety of uses in the treatment of ocular disease, and several reports have shown both acute and chronic increases in intraocular pressure (IOP) following injection of these drugs. This article will review these data and their relevance to glaucoma.
</p>
<h1><span class="mw-headline" id="History">History</span></h1>
<p>In 2004, pegatinib (Macugen) was the first anti-VEGF agent approved for intravitreal injection (IVI) for the treatment of neovascular age-related macular degeneration (ARMD).<sup id="cite_ref-gragoudas1_1-0" class="reference"><a href="#cite_note-gragoudas1-1">&#91;1&#93;</a></sup> Since then, a host of other agents including ranibizumab (Lucentis), bevacizumab (Avastin), aflibercept (Eylea), and more recently, Faricimab (Vabysmo) have been approved for the treatment of macular edema secondary to diabetes, branch retinal vein occlusion, and central retinal vein occlusions as well as degenerative myopia.<sup id="cite_ref-hoguet2_2-0" class="reference"><a href="#cite_note-hoguet2-2">&#91;2&#93;</a></sup> <sup id="cite_ref-markham3_3-0" class="reference"><a href="#cite_note-markham3-3">&#91;3&#93;</a></sup>
</p><p>Soon after the introduction of these drugs, reports of acute spikes in IOP began to emerge and have been reported in multiple studies.<sup id="cite_ref-elchehab4_4-0" class="reference"><a href="#cite_note-elchehab4-4">&#91;4&#93;</a></sup> <sup id="cite_ref-falkenstein5_5-0" class="reference"><a href="#cite_note-falkenstein5-5">&#91;5&#93;</a></sup> <sup id="cite_ref-farhood6_6-0" class="reference"><a href="#cite_note-farhood6-6">&#91;6&#93;</a></sup> <sup id="cite_ref-frenkel7_7-0" class="reference"><a href="#cite_note-frenkel7-7">&#91;7&#93;</a></sup> <sup id="cite_ref-gismondi8_8-0" class="reference"><a href="#cite_note-gismondi8-8">&#91;8&#93;</a></sup> <sup id="cite_ref-hollands9_9-0" class="reference"><a href="#cite_note-hollands9-9">&#91;9&#93;</a></sup> <sup id="cite_ref-kiddee10_10-0" class="reference"><a href="#cite_note-kiddee10-10">&#91;10&#93;</a></sup> <sup id="cite_ref-kim11_11-0" class="reference"><a href="#cite_note-kim11-11">&#91;11&#93;</a></sup> <sup id="cite_ref-kotliar12_12-0" class="reference"><a href="#cite_note-kotliar12-12">&#91;12&#93;</a></sup> <sup id="cite_ref-lim13_13-0" class="reference"><a href="#cite_note-lim13-13">&#91;13&#93;</a></sup> <sup id="cite_ref-mojica14_14-0" class="reference"><a href="#cite_note-mojica14-14">&#91;14&#93;</a></sup> <sup id="cite_ref-omay15_15-0" class="reference"><a href="#cite_note-omay15-15">&#91;15&#93;</a></sup> <sup id="cite_ref-sharei16_16-0" class="reference"><a href="#cite_note-sharei16-16">&#91;16&#93;</a></sup> <sup id="cite_ref-wu17_17-0" class="reference"><a href="#cite_note-wu17-17">&#91;17&#93;</a></sup> Nonetheless, the MARINA and ANCHOR clinical trials, which demonstrated the efficacy of Bevacizumab for treatment of neovascular age-related macular degeneration, found that these spikes were transient.<sup id="cite_ref-rosenfeld18_18-0" class="reference"><a href="#cite_note-rosenfeld18-18">&#91;18&#93;</a></sup> <sup id="cite_ref-brown19_19-0" class="reference"><a href="#cite_note-brown19-19">&#91;19&#93;</a></sup> However, in a post-hoc analysis by Bakri et al, patients treated with anti-VEGF agents were found to have a greater likelihood of an increase in pre-injection IOP ≥6 mmHg from baseline and a concurrent IOP of ≥21 mmHg or ≥25 mmHg at ≥2 consecutive visits compared to those who received sham injections over a 24-month follow up period.<sup id="cite_ref-bakri20_20-0" class="reference"><a href="#cite_note-bakri20-20">&#91;20&#93;</a></sup> Since then, a host of studies have been conducted demonstrating a sustained increase IOP following anti-VEGF injection. Given that the same aging population for which these drugs are most often employed is also at risk for developing glaucoma, understanding the potential for short- and long-term IOP spikes and the impact of anti-VEGF injections on glaucomatous progression is of critical importance. In this article, we will discuss data on the post-injection spike, long-term sustained IOP elevation, the impact on glaucomatous progression in susceptible eyes, and possible prophylactic measures that may be taken. 
</p>
<h1><span class="mw-headline" id="Post-injection_spike_in_IOP">Post-injection spike in IOP</span></h1>
<p>A post-injection spike in IOP is a logical outcome as the eye undergoes volume expansion. Summing the effect of 14 studies on short-term pressure effects of anti-VEGF injections (median 60 injected eyes, 12-853), Hoguet et al found 100% of patients had an increase in IOP (mean ≤18 mmHg pre-injection) to 28.3-55.2 at 1 minute; at 10-15 minutes the IOP decreased to 22.8-25.8 mmHg, and at 30 minutes it further decreased to 17.6-24.5 mmHg2. IOP continued to decrease over time in studies that captured longer time points, suggesting these IOP spikes were transient. Typically, post-injection IOP returned to baseline within 1 hour. 
</p><p>These findings were also supported by a recent large meta-analysis of 46 articles (2872 eyes), that reported that the mean difference in IOP after anti-VEGF injection (rise above pre-injection) was 23.41 mm Hg immediately after injection, 2.51 mm Hg at 30 minutes, −0.63 one day after injection, and back to baseline by 1 week. <sup id="cite_ref-:0_21-0" class="reference"><a href="#cite_note-:0-21">&#91;21&#93;</a></sup> 
</p>
<h1><span class="mw-headline" id="Long-term_sustained_IOP_elevation">Long-term sustained IOP elevation</span></h1>
<p>The best evidence for sustained IOP elevation following anti-VEGF injections comes from a post-hoc analysis of the MARINA and ANCHOR trials by Bakri et al which found the incidence of a &gt;6 mmHg IOP spike from baseline in at least one visit with a simultaneous IOP ≥21 mmHg was 23.6% in the 0.3mg ranibizumab group, 26.1% in the 0.5 mg ranibizumab group, and 13.6% in the sham injection groups.<sup id="cite_ref-bakri20_20-1" class="reference"><a href="#cite_note-bakri20-20">&#91;20&#93;</a></sup> 
Several studies have replicated these findings in different populations as shown in the table below.<sup id="cite_ref-alabdullah21_22-0" class="reference"><a href="#cite_note-alabdullah21-22">&#91;22&#93;</a></sup> <sup id="cite_ref-atchison22_23-0" class="reference"><a href="#cite_note-atchison22-23">&#91;23&#93;</a></sup> <sup id="cite_ref-choi23_24-0" class="reference"><a href="#cite_note-choi23-24">&#91;24&#93;</a></sup> <sup id="cite_ref-freund24_25-0" class="reference"><a href="#cite_note-freund24-25">&#91;25&#93;</a></sup> <sup id="cite_ref-hoang25_26-0" class="reference"><a href="#cite_note-hoang25-26">&#91;26&#93;</a></sup> <sup id="cite_ref-kim26_27-0" class="reference"><a href="#cite_note-kim26-27">&#91;27&#93;</a></sup> <sup id="cite_ref-mathalone27_28-0" class="reference"><a href="#cite_note-mathalone27-28">&#91;28&#93;</a></sup> <sup id="cite_ref-silva28_29-0" class="reference"><a href="#cite_note-silva28-29">&#91;29&#93;</a></sup> <sup id="cite_ref-bilgic29_30-0" class="reference"><a href="#cite_note-bilgic29-30">&#91;30&#93;</a></sup> <sup id="cite_ref-gabrielle30_31-0" class="reference"><a href="#cite_note-gabrielle30-31">&#91;31&#93;</a></sup> <sup id="cite_ref-cui31_32-0" class="reference"><a href="#cite_note-cui31-32">&#91;32&#93;</a></sup> Several cases have also been documented in which sustained IOP elevation following injection necessitated surgical filtration procedures.<sup id="cite_ref-eadie32_33-0" class="reference"><a href="#cite_note-eadie32-33">&#91;33&#93;</a></sup> <sup id="cite_ref-skalicky33_34-0" class="reference"><a href="#cite_note-skalicky33-34">&#91;34&#93;</a></sup> <sup id="cite_ref-du34_35-0" class="reference"><a href="#cite_note-du34-35">&#91;35&#93;</a></sup> In fact, a case-control study in Canada found that eyes with ≥7 annual injections had a significantly greater odds ratio of undergoing glaucoma drainage surgery than controls.<sup id="cite_ref-eadie32_33-1" class="reference"><a href="#cite_note-eadie32-33">&#91;33&#93;</a></sup> This finding is bolstered by several studies showing total number of injections to be a risk factor for sustained IOP elevation as well as greater frequency of injections and pre-existing diagnosis of glaucoma prior to initiation of IVIs.<sup id="cite_ref-hoang25_26-1" class="reference"><a href="#cite_note-hoang25-26">&#91;26&#93;</a></sup><sup id="cite_ref-mathalone27_28-1" class="reference"><a href="#cite_note-mathalone27-28">&#91;28&#93;</a></sup><sup id="cite_ref-pershing35_36-0" class="reference"><a href="#cite_note-pershing35-36">&#91;36&#93;</a></sup> <sup id="cite_ref-segal36_37-0" class="reference"><a href="#cite_note-segal36-37">&#91;37&#93;</a></sup> <sup id="cite_ref-beato37_38-0" class="reference"><a href="#cite_note-beato37-38">&#91;38&#93;</a></sup> <sup id="cite_ref-good38_39-0" class="reference"><a href="#cite_note-good38-39">&#91;39&#93;</a></sup> <sup id="cite_ref-hoang39_40-0" class="reference"><a href="#cite_note-hoang39-40">&#91;40&#93;</a></sup> <sup id="cite_ref-demirel40_41-0" class="reference"><a href="#cite_note-demirel40-41">&#91;41&#93;</a></sup>
</p>
<table class="wikitable">
<tbody><tr>
<th>Author
</th>
<th>Definition of IOP elevation
</th>
<th># Eyes
</th>
<th>Mean #  Injections
</th>
<th>Mean Follow-Up (Weeks)
</th>
<th>Preinjection IOP (Mean)
</th>
<th>IOP at Study End (Mean)
</th>
<th>% With Sustained IOP Elevation
</th></tr>
<tr>
<td>Al-Abdullah 2015</td>
<td>IOP ≥6 mmHg above baseline, increase &gt;20%, or IOP &gt;24 mmHg on ≥2 consecutive visits</td>
<td>760</td>
<td>3.4</td>
<td>78.0</td>
<td>17.2</td>
<td>17</td>
<td>5.8%
</td></tr>
<tr>
<td>Atchison 2018</td>
<td>IOP ≥6 mmHg above baseline and &gt;21 mmHg on ≥2 consecutive visits</td>
<td>23776</td>
<td>7.9</td>
<td>96.6</td>
<td>15.3</td>
<td>14.4</td>
<td>2.6%
</td></tr>
<tr>
<td>Choi 2011</td>
<td>IOP &gt;25 mmHg on 2 separate visits</td>
<td>155</td>
<td>7.0</td>
<td>57.4</td>
<td>14.4</td>
<td>15.3</td>
<td>5.5%
</td></tr>
<tr>
<td>Freund 2015</td>
<td>IOP &gt;21 mmHg for ≥2 consecutive visits</td>
<td>595</td>
<td>16.0</td>
<td>96.0</td>
<td>15</td>
<td>NR</td>
<td>8.4%
</td></tr>
<tr>
<td>Hoang 2012</td>
<td>IOP &gt;5 mmHg above baseline on ≥2 consecutive visits</td>
<td>207</td>
<td>20.8</td>
<td>148.6</td>
<td>NR</td>
<td>NR</td>
<td>11.6%
</td></tr>
<tr>
<td>Kim 2014</td>
<td>IOP &gt;5 mmHg above baseline on ≥2 consecutive visits</td>
<td>629</td>
<td>9.5</td>
<td>151.7</td>
<td>14.1</td>
<td>14.2</td>
<td>3.7%
</td></tr>
<tr>
<td>Mathalone 2012</td>
<td>IOP ≥22 mmHg and change from baseline of ≥6 mmHg recorded on  ≥2 consecutive visits and lasting ≥30 days</td>
<td>201</td>
<td>4.0 (median)</td>
<td>68.0</td>
<td>14.8</td>
<td>15.5</td>
<td>11.0%
</td></tr>
<tr>
<td>Silva 2013</td>
<td>NR</td>
<td>210</td>
<td>6.1</td>
<td>104.0</td>
<td>NR</td>
<td>NR</td>
<td>6.4%
</td></tr>
<tr>
<td>Bilgic 2020</td>
<td>IOP ≥6 mmHg above baseline and/or &gt;24mmHg on 2 or more consecutive visits</td>
<td>1021</td>
<td>NR</td>
<td>183.7</td>
<td>NR</td>
<td>NR</td>
<td>8.9%
</td></tr>
<tr>
<td>Gabrielle 2020</td>
<td>IOP ≥6 mmHg above baseline and &gt;21mmHg at a single visit</td>
<td>3429</td>
<td>NR</td>
<td>52.0</td>
<td>14.4</td>
<td>13.9</td>
<td>4.9%
</td></tr>
<tr>
<td>Cui 2019</td>
<td>having filled a prescription for IOP-lowering medication or having a new diagnosis of glaucoma, glaucoma suspect, or ocular hypertension</td>
<td>17113</td>
<td>NR</td>
<td>135.2</td>
<td>NR</td>
<td>NR</td>
<td>12.0%
</td></tr></tbody></table>
<p><b>NR = not recorded</b>
</p><p><br />
A handful of reports have been published in which no increased risk of IOP elevation over a 1-40 month period was found.<sup id="cite_ref-boyer41_42-0" class="reference"><a href="#cite_note-boyer41-42">&#91;42&#93;</a></sup> <sup id="cite_ref-gado42_43-0" class="reference"><a href="#cite_note-gado42-43">&#91;43&#93;</a></sup> <sup id="cite_ref-g.C3.BCler43_44-0" class="reference"><a href="#cite_note-g.C3.BCler43-44">&#91;44&#93;</a></sup> <sup id="cite_ref-rusu44_45-0" class="reference"><a href="#cite_note-rusu44-45">&#91;45&#93;</a></sup> <sup id="cite_ref-wehrli45_46-0" class="reference"><a href="#cite_note-wehrli45-46">&#91;46&#93;</a></sup> <sup id="cite_ref-yoganathan46_47-0" class="reference"><a href="#cite_note-yoganathan46-47">&#91;47&#93;</a></sup> Only one of these studies, however, explicitly defines IOP elevation. Wehrli et al found no significant difference in sustained IOP elevation between 270 injected eyes and 195 control eyes with sustained IOP elevation defined as ≥22mmHg on 2 consecutive visits or &gt;26mmHg on a single visit over a 5 year period.<sup id="cite_ref-wehrli45_46-1" class="reference"><a href="#cite_note-wehrli45-46">&#91;46&#93;</a></sup>  Compared to the studies which did find an increased risk of IOP elevation in anti-VEGF-treated eyes, these studies were limited by smaller sample sizes (average 111 vs 4,372 eyes) and shorter follow-up periods (72 vs. 106 weeks). 
Several risk factors have been shown to be associated with sustained IOP elevation following injection. First, and perhaps least surprisingly, is total number of injections. In a multitude of studies the total number of injections has been shown to be associated with an increased risk of sustained IOP elevation.<sup id="cite_ref-hoang25_26-2" class="reference"><a href="#cite_note-hoang25-26">&#91;26&#93;</a></sup> <sup id="cite_ref-bilgic29_30-1" class="reference"><a href="#cite_note-bilgic29-30">&#91;30&#93;</a></sup> <sup id="cite_ref-eadie32_33-2" class="reference"><a href="#cite_note-eadie32-33">&#91;33&#93;</a></sup> <sup id="cite_ref-pershing35_36-1" class="reference"><a href="#cite_note-pershing35-36">&#91;36&#93;</a></sup> <sup id="cite_ref-segal36_37-1" class="reference"><a href="#cite_note-segal36-37">&#91;37&#93;</a></sup> <sup id="cite_ref-beato37_38-1" class="reference"><a href="#cite_note-beato37-38">&#91;38&#93;</a></sup> <sup id="cite_ref-hoang39_40-1" class="reference"><a href="#cite_note-hoang39-40">&#91;40&#93;</a></sup> Some have suggested that the an accumulation of some component of the injection may effectively clog the trabecular meshwork, which is supported by the decrease in outflow facility seen by Schiøtz tonography.<sup id="cite_ref-wen47_48-0" class="reference"><a href="#cite_note-wen47-48">&#91;48&#93;</a></sup> Importantly, a pre-existing glaucoma diagnosis was found to be associated with sustained IOP elevation defined as ≥22 mmHg lasting ≥30 days, recorded on at least two separate visits and a change from baseline of &gt;6 mm Hg.<sup id="cite_ref-good38_39-1" class="reference"><a href="#cite_note-good38-39">&#91;39&#93;</a></sup> Another study similarly found an association with preexisting glaucoma and sustained IOP elevation defined as a rise in IOP above baseline by ≥6 mmHg and/or &gt;24 mmHg on 2 or more consecutive visits.<sup id="cite_ref-bilgic29_30-2" class="reference"><a href="#cite_note-bilgic29-30">&#91;30&#93;</a></sup> Other risk factors studied have included higher injection volume and specific anti-VEGF agents, with two studies finding ranibizumab to be associated with more IOP elevation than aflibercept.<sup id="cite_ref-freund24_25-1" class="reference"><a href="#cite_note-freund24-25">&#91;25&#93;</a></sup><sup id="cite_ref-bilgic29_30-3" class="reference"><a href="#cite_note-bilgic29-30">&#91;30&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Development_of_Open-Angle_Glaucoma">Development of Open-Angle Glaucoma</span></h1>
<p>Whether or not the use of anti-VEGF agents is associated with the development of glaucoma is of great interest. Cui et. al demonstrated that patients receiving more injections (14 or more injections at 2 y follow-up and 20 or more injections at 3 y follow-up) had higher odds of initiating IOP-lowering therapy or having a new diagnosis of glaucoma.<sup id="cite_ref-cui31_32-1" class="reference"><a href="#cite_note-cui31-32">&#91;32&#93;</a></sup> Filek et al found an increased cup-to-disc ratio and cup volume was observed over a 2 year study period in patients undergoing treatment with ranibizumab for diabetic macular edema, however there was no significant trend in deterioration of visual fields.<sup id="cite_ref-filek48_49-0" class="reference"><a href="#cite_note-filek48-49">&#91;49&#93;</a></sup> Similarly, Gómez-Mariscal et al found significant cup widening, deepening, and RNFL thinning seen in eyes treated with anti-VEGF agents.<sup id="cite_ref-g.C3.B3mezmariscal49_50-0" class="reference"><a href="#cite_note-g.C3.B3mezmariscal49-50">&#91;50&#93;</a></sup> Regarding a diagnosis of glaucoma, Wingard et al found the incidence of glaucoma or ocular hypertension diagnosis was significantly higher in patients undergoing a higher frequency of anti-VEGF injection for AMD for each additional injection over the most injection-intense 6 month period for any given subject.<sup id="cite_ref-wingard50_51-0" class="reference"><a href="#cite_note-wingard50-51">&#91;51&#93;</a></sup> Furthermore, several studies have found an increased incidence of surgical filtration surgeries among patients undergoing repeated anti-VEGF injections.<sup id="cite_ref-eadie32_33-3" class="reference"><a href="#cite_note-eadie32-33">&#91;33&#93;</a></sup> <sup id="cite_ref-skalicky33_34-1" class="reference"><a href="#cite_note-skalicky33-34">&#91;34&#93;</a></sup> <sup id="cite_ref-du34_35-1" class="reference"><a href="#cite_note-du34-35">&#91;35&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Development_of_Angle-Closure_Glaucoma">Development of Angle-Closure Glaucoma</span></h1>
<p>Several case reports describe acute angle-closure glaucoma temporally related to intravitreal injection. Jeong et al described a case in a hyperopic eye and proposed that eyes with short axial lengths are at higher risk due to less room to accommodate for the injected volume of fluid.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52">&#91;52&#93;</a></sup> They performed a prophylactic peripheral iridotomy in the contralateral eye to prevent future post injection attacks. Alkin et al suggested that anterior chamber depth might shallow after intravitreal injection in correlation with the acute rise in IOP due to increased posterior chamber volume.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53">&#91;53&#93;</a></sup>&#160; Kim and Baek described a case of angle closure in an eye that was not hyperopic, however they suggested that zonulopathy and mydriasis might have contributed to the patient’s angle-closure. These reports indicate that it might be prudent to assess eyes for risk of angle closure, including gonioscopy, before initiating intravitreal injections.<sup id="cite_ref-54" class="reference"><a href="#cite_note-54">&#91;54&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Exacerbation_of_Glaucoma">Exacerbation of Glaucoma</span></h1>
<p>Exacerbation of glaucoma following the use of anti-VEGF agents has been documented. In 2017, Eadie et al used a big-data approach to investigate the risk of necessitating glaucoma surgery in all patients in British Columbia receiving bevacizumab injections for ARMD over a four-year period. Using 10:1 matched controls for age, glaucoma diagnosis, data, and follow-up time, there was an adjusted risk ratio of 2.48 for undergoing glaucoma surgery in patients receiving bevacizumab.<sup id="cite_ref-eadie32_33-4" class="reference"><a href="#cite_note-eadie32-33">&#91;33&#93;</a></sup> Furthermore, 7 or more injections was associated with an increased risk of surgery.  
</p><p>It has been proposed that glaucoma patients have a larger and more persistent IOP spike after injections which may result in progression of disease. Kim et al found that eyes with preexisting glaucoma take longer to recover from the acute spike after injection. They found that fewer eyes with glaucoma had reached an IOP &lt; 30 mm Hg at 5, 10, and 15 minutes after injection compared with non-glaucomatous eyes.<sup id="cite_ref-kim11_11-1" class="reference"><a href="#cite_note-kim11-11">&#91;11&#93;</a></sup>
</p><p>In 2019, Du et al found a higher rate of visual field decline, glaucoma surgery, and RNFL thinning in injected glaucomatous eyes over an eight year period compared to those not undergoing injection.<sup id="cite_ref-du34_35-2" class="reference"><a href="#cite_note-du34-35">&#91;35&#93;</a></sup> This study was limited by a small sample size and a high percentage of retinal vein occlusions in the glaucomatous group (which are associated with RNFL thinning).<sup id="cite_ref-g.C3.B3mezmariscal51_55-0" class="reference"><a href="#cite_note-g.C3.B3mezmariscal51-55">&#91;55&#93;</a></sup> Nonetheless, significant RNFL thinning and cup widening following repeated injections has been observed in another study by Gómez-Mariscal et al in which ARMD was the primary indication for anti-VEGF injection.<sup id="cite_ref-g.C3.B3mezmariscal49_50-1" class="reference"><a href="#cite_note-g.C3.B3mezmariscal49-50">&#91;50&#93;</a></sup>
</p>
<h1><span class="mw-headline" id="Post-Injection_Changes_to_Retinal_Nerve_Fiber_Layer">Post-Injection Changes to Retinal Nerve Fiber Layer</span></h1>
<p>Given the risk of IOP spike after multiple IVIs, the impact of injections on RNFL loss has also been studied, with mixed results. A meta-analysis by de Vries et al included 4 studies on this topic and concluded that RNFL was significantly reduced by −3.34 µm at 1 year.<sup id="cite_ref-:0_21-1" class="reference"><a href="#cite_note-:0-21">&#91;21&#93;</a></sup> This being said, only 1 of the 4 individual studies (Martinez-de-la-Casa et al) inferred that injections were associated with thinning.<sup id="cite_ref-:1_56-0" class="reference"><a href="#cite_note-:1-56">&#91;56&#93;</a></sup>
</p><p>In the prospective study by Martinez-de-la-Casa et al, 49 treatment eyes and 17 control eyes were compared over a span of one year.&#160; They demonstrated significant RNFL thinning in IVI treated eyes, while no change was noted in the control group. <sup id="cite_ref-:1_56-1" class="reference"><a href="#cite_note-:1-56">&#91;56&#93;</a></sup>&#160;Jo et al found that RNFL was not reduced in eyes treated with ranibizumab and suggested that areas of RNFL thinning might more likely be related to the macular lesion rather than the injections.<sup id="cite_ref-57" class="reference"><a href="#cite_note-57">&#91;57&#93;</a></sup> Entezari et al also found that RNFL was similar to baseline at 1 year in eyes injected with bevacizumab, but similarly concluded that temporary RNFL thinning might be related to changes in macular edema.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58">&#91;58&#93;</a></sup> Parlak et al found thinning in both injected eyes and control eyes without a difference between the groups.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59">&#91;59&#93;</a></sup>
</p><p>Outside of de Vries and colleagues’ meta-analysis, other studies have largely failed to show an association of IVIs and RNFL loss.&#160; Valverde-Megias et al followed 20 injected eyes and their contralateral control eyes for 8 years and demonstrated RNFL loss in both groups but no difference in RNFL thickness between injected and control eyes.<sup id="cite_ref-60" class="reference"><a href="#cite_note-60">&#91;60&#93;</a></sup> Horsley et al reported no RNFL loss in a retrospective study of injected eyes that underwent RNFL measurement over the span of at least 1 year.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61">&#91;61&#93;</a></sup> Swaminathan et al reported no difference in RNFL thinning per year in a retrospective study of 53 injected eyes versus fellow eye controls.<sup id="cite_ref-62" class="reference"><a href="#cite_note-62">&#91;62&#93;</a></sup> &#160;Soheilian et al randomized patients undergoing IVI to receive a prophylactic anterior chamber paracentesis or standard protocol without paracentesis. They noted acute IOP spikes and RNFL loss at 3 months in eyes undergoing standard IVI protocols, while this was prevented in eyes receiving a prophylactic anterior chamber paracentesis.<sup id="cite_ref-:2_63-0" class="reference"><a href="#cite_note-:2-63">&#91;63&#93;</a></sup>
</p><p>If there is an association between injections and RNFL loss, then it is likely that some but not all eyes are susceptible, and that larger studies are necessary to adequately describe this relationship. It must also be noted that interpretation of these studies is difficult given that RNFL thickness might be impacted by injections as well as the underlying retinal pathology.
</p>
<h1><span class="mw-headline" id="Proposed_Mechanism_for_sustained_IOP_increase_following_anti-VEGF_Injection">Proposed Mechanism for sustained IOP increase following anti-VEGF Injection</span></h1>
<p>Multiple mechanisms have been proposed to explain a sustained increase in IOP following anti-VEGF injections. A decrease in outflow facility has been one proposed mechanism secondary to either obstruction by some component of the injection or an inflammatory response.<sup id="cite_ref-bracha52_64-0" class="reference"><a href="#cite_note-bracha52-64">&#91;64&#93;</a></sup> Supporting this theory is one study which found outflow facility to be significantly decreased in eyes receiving anti-VEGF therapy as measure by Schiøtz tonography when patients had ≥20 intravitreal injections.<sup id="cite_ref-wen47_48-1" class="reference"><a href="#cite_note-wen47-48">&#91;48&#93;</a></sup> Microparticle obstruction of the trabecular meshwork is one possibility that has been explored by multiple groups, whether due to high-molecular weight protein aggregates from medication packaging or silicone microdroplets from syringes.<sup id="cite_ref-kahook53_65-0" class="reference"><a href="#cite_note-kahook53-65">&#91;65&#93;</a></sup> <sup id="cite_ref-liu54_66-0" class="reference"><a href="#cite_note-liu54-66">&#91;66&#93;</a></sup> <sup id="cite_ref-bakri55_67-0" class="reference"><a href="#cite_note-bakri55-67">&#91;67&#93;</a></sup> Alternatively, a direct inflammatory effect of anti-VEGF agents on trabecular meshwork cells has been explored. Kahook et al demonstrated 4 mg/ml bevacizumab slows the metabolism and replication of trabecular meshwork cells in vitro, possibly contributing to decreased outflow facility.<sup id="cite_ref-kahook56_68-0" class="reference"><a href="#cite_note-kahook56-68">&#91;68&#93;</a></sup> Additionally, an inflammatory response to monomer antibodies, protein aggregates or high molecular weight molecules may lead to a trabeculitis with impaired aqueous humor outflow.<sup id="cite_ref-georgopoulos57_69-0" class="reference"><a href="#cite_note-georgopoulos57-69">&#91;69&#93;</a></sup> <sup id="cite_ref-sniegowski58_70-0" class="reference"><a href="#cite_note-sniegowski58-70">&#91;70&#93;</a></sup> 
</p><p>Another proposed mechanism is related to the inhibition of nitric oxide synthase by anti-VEGF agents.<sup id="cite_ref-71" class="reference"><a href="#cite_note-71">&#91;71&#93;</a></sup> This results in a decrease in nitric oxide which results in a downstream movement of potassium and calcium in trabecular meshwork cells, alteration of trabecular meshwork cell contractility, and ultimately decreased aqueous outflow through intercellular spaces.<sup id="cite_ref-72" class="reference"><a href="#cite_note-72">&#91;72&#93;</a></sup><sup id="cite_ref-73" class="reference"><a href="#cite_note-73">&#91;73&#93;</a></sup> Nitric oxide’s effect on smooth muscle contractility has been linked to systemic hypertension in patients receiving anti-VEGF injections, and thus has also been proposed to increase outflow resistance in the eye.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74">&#91;74&#93;</a></sup> 
</p>
<h1><span class="mw-headline" id="Management_and_Prevention">Management and Prevention</span></h1>
<p>Several prophylactic measures have been suggested to prevent the acute post-injection IOP spike in patients for whom large IOP fluctuations pose a risk such as those with advanced glaucomatous disease. Pre-injection topical glaucoma medications have proven successful in limiting post-injection IOP elevation in several studies.<sup id="cite_ref-elchehab60_75-0" class="reference"><a href="#cite_note-elchehab60-75">&#91;75&#93;</a></sup> <sup id="cite_ref-kozobolis61_76-0" class="reference"><a href="#cite_note-kozobolis61-76">&#91;76&#93;</a></sup> <sup id="cite_ref-ozcaliskan62_77-0" class="reference"><a href="#cite_note-ozcaliskan62-77">&#91;77&#93;</a></sup> <sup id="cite_ref-pece63_78-0" class="reference"><a href="#cite_note-pece63-78">&#91;78&#93;</a></sup> <sup id="cite_ref-theoulakis64_79-0" class="reference"><a href="#cite_note-theoulakis64-79">&#91;79&#93;</a></sup> <sup id="cite_ref-carnotam.C3.A9ndez65_80-0" class="reference"><a href="#cite_note-carnotam.C3.A9ndez65-80">&#91;80&#93;</a></sup> Additionally, the presence of vitreous reflux following injection has been associated with a lower IOP spike.<sup id="cite_ref-carnotam.C3.A9ndez65_80-1" class="reference"><a href="#cite_note-carnotam.C3.A9ndez65-80">&#91;80&#93;</a></sup><sup id="cite_ref-knecht66_81-0" class="reference"><a href="#cite_note-knecht66-81">&#91;81&#93;</a></sup> <sup id="cite_ref-pang67_82-0" class="reference"><a href="#cite_note-pang67-82">&#91;82&#93;</a></sup> Other factors found to prevent acute IOP spikes include ocular decompression by cotton swabs,<sup id="cite_ref-gregori68_83-0" class="reference"><a href="#cite_note-gregori68-83">&#91;83&#93;</a></sup> a history of glaucoma surgery,<sup id="cite_ref-lam69_84-0" class="reference"><a href="#cite_note-lam69-84">&#91;84&#93;</a></sup> pseudophakia<sup id="cite_ref-bilgic29_30-4" class="reference"><a href="#cite_note-bilgic29-30">&#91;30&#93;</a></sup><sup id="cite_ref-wingard50_51-1" class="reference"><a href="#cite_note-wingard50-51">&#91;51&#93;</a></sup>, and anterior chamber paracentesis.<sup id="cite_ref-knip70_85-0" class="reference"><a href="#cite_note-knip70-85">&#91;85&#93;</a></sup><sup id="cite_ref-:2_63-1" class="reference"><a href="#cite_note-:2-63">&#91;63&#93;</a></sup> 
</p><p>Regarding sustained IOP elevation following long-term anti-VEGF therapy, no successful mitigation strategy has been thoroughly investigated. Regarding the theory that silicone oil originating from coating on syringes ultimately occludes the trabecular meshwork, Lode et al has described a method of compounding anti-VEGF agents in silicone-free syringes, however more research needs to be done on its efficacy.<sup id="cite_ref-86" class="reference"><a href="#cite_note-86">&#91;86&#93;</a></sup> Wingard et al suggested that patients with known risk factors for sustained IOP elevation should consider lower frequency injections at initiation of therapy and extension of the inter-injection interval.<sup id="cite_ref-wingard50_51-2" class="reference"><a href="#cite_note-wingard50-51">&#91;51&#93;</a></sup> Nonetheless, foregoing anti-VEGF therapy or extending the intervals of injection risks progression of the diseases these agents treat. Ultimately, patients should be monitored for development of ocular hypertension, and those who develop a sustained increase in IOP should be evaluated periodically for glaucomatous changes via an optic nerve OCT and visual field testing. Referral to a glaucoma specialist should be considered in patients with concerning features. 
 
</p>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-gragoudas1-1"><span class="mw-cite-backlink"><a href="#cite_ref-gragoudas1_1-0">↑</a></span> <span class="reference-text">Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-16.</span>
</li>
<li id="cite_note-hoguet2-2"><span class="mw-cite-backlink"><a href="#cite_ref-hoguet2_2-0">↑</a></span> <span class="reference-text">Hoguet A, Chen PP, Junk AK, Mruthyunjaya P, Nouri-Mahdavi K, Radhakrishnan S, et al. The Effect of Anti-Vascular Endothelial Growth Factor Agents on Intraocular Pressure and Glaucoma: A Report by the American Academy of Ophthalmology. Ophthalmology. 2019;126(4):611-22.</span>
</li>
<li id="cite_note-markham3-3"><span class="mw-cite-backlink"><a href="#cite_ref-markham3_3-0">↑</a></span> <span class="reference-text">Markham A. Brolucizumab: First Approval. Drugs. 2019;79(18):1997-2000.</span>
</li>
<li id="cite_note-elchehab4-4"><span class="mw-cite-backlink"><a href="#cite_ref-elchehab4_4-0">↑</a></span> <span class="reference-text">El Chehab H, Agard E, Russo A, Boujnah Y, Dot C. Intraocular Pressure Spikes after Aflibercept Intravitreal Injections. Ophthalmologica. 2016;236(1):43-7.</span>
</li>
<li id="cite_note-falkenstein5-5"><span class="mw-cite-backlink"><a href="#cite_ref-falkenstein5_5-0">↑</a></span> <span class="reference-text">Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina. 2007;27(8):1044-7.</span>
</li>
<li id="cite_note-farhood6-6"><span class="mw-cite-backlink"><a href="#cite_ref-farhood6_6-0">↑</a></span> <span class="reference-text">Farhood QK, Twfeeq SM. Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients. Clin Ophthalmol. 2014;8:599-604.</span>
</li>
<li id="cite_note-frenkel7-7"><span class="mw-cite-backlink"><a href="#cite_ref-frenkel7_7-0">↑</a></span> <span class="reference-text">Frenkel RE, Mani L, Toler AR, Frenkel MP. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol. 2007;143(6):1034-5.</span>
</li>
<li id="cite_note-gismondi8-8"><span class="mw-cite-backlink"><a href="#cite_ref-gismondi8_8-0">↑</a></span> <span class="reference-text">Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma. 2009;18(9):658-61.</span>
</li>
<li id="cite_note-hollands9-9"><span class="mw-cite-backlink"><a href="#cite_ref-hollands9_9-0">↑</a></span> <span class="reference-text">Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol. 2007;42(6):807-11.</span>
</li>
<li id="cite_note-kiddee10-10"><span class="mw-cite-backlink"><a href="#cite_ref-kiddee10_10-0">↑</a></span> <span class="reference-text">Kiddee W, Montriwet M. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents. PLoS One. 2015;10(9):e0137833.</span>
</li>
<li id="cite_note-kim11-11"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-kim11_11-0">11.0</a></sup> <sup><a href="#cite_ref-kim11_11-1">11.1</a></sup></span> <span class="reference-text">Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(6):930-4.e1.</span>
</li>
<li id="cite_note-kotliar12-12"><span class="mw-cite-backlink"><a href="#cite_ref-kotliar12_12-0">↑</a></span> <span class="reference-text">Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand. 2007;85(7):777-81.</span>
</li>
<li id="cite_note-lim13-13"><span class="mw-cite-backlink"><a href="#cite_ref-lim13_13-0">↑</a></span> <span class="reference-text">Lim HB, Kim MS, Jo YJ, Kim JY. Short-Term Visual Acuity and Intraocular Pressure Changes and Their Correlation after Anti-Vascular Endothelial Growth Factor Injection. Ophthalmologica. 2016;236(1):36-42.</span>
</li>
<li id="cite_note-mojica14-14"><span class="mw-cite-backlink"><a href="#cite_ref-mojica14_14-0">↑</a></span> <span class="reference-text">Mojica G, Hariprasad SM, Jager RD, Mieler WF. Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol. 2008;92(4):584.</span>
</li>
<li id="cite_note-omay15-15"><span class="mw-cite-backlink"><a href="#cite_ref-omay15_15-0">↑</a></span> <span class="reference-text">Omay E, Elgin U, Sen E, Yilmazbas P. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness. Int Ophthalmol. 2016;36(5):665-70.</span>
</li>
<li id="cite_note-sharei16-16"><span class="mw-cite-backlink"><a href="#cite_ref-sharei16_16-0">↑</a></span> <span class="reference-text">Sharei V, Höhn F, Köhler T, Hattenbach LO, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20(1):174-9.</span>
</li>
<li id="cite_note-wu17-17"><span class="mw-cite-backlink"><a href="#cite_ref-wu17_17-0">↑</a></span> <span class="reference-text">Wu L, Evans T. [Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab]. Arch Soc Esp Oftalmol. 2010;85(11):364-9.</span>
</li>
<li id="cite_note-rosenfeld18-18"><span class="mw-cite-backlink"><a href="#cite_ref-rosenfeld18_18-0">↑</a></span> <span class="reference-text">Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-31.</span>
</li>
<li id="cite_note-brown19-19"><span class="mw-cite-backlink"><a href="#cite_ref-brown19_19-0">↑</a></span> <span class="reference-text">Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-44.</span>
</li>
<li id="cite_note-bakri20-20"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-bakri20_20-0">20.0</a></sup> <sup><a href="#cite_ref-bakri20_20-1">20.1</a></sup></span> <span class="reference-text">Bakri SJ, Moshfeghi DM, Francom S, Rundle AC, Reshef DS, Lee PP, et al. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials. Ophthalmology. 2014;121(5):1102-8.</span>
</li>
<li id="cite_note-:0-21"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:0_21-0">21.0</a></sup> <sup><a href="#cite_ref-:0_21-1">21.1</a></sup></span> <span class="reference-text">de Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10:13248</span>
</li>
<li id="cite_note-alabdullah21-22"><span class="mw-cite-backlink"><a href="#cite_ref-alabdullah21_22-0">↑</a></span> <span class="reference-text">Al-Abdullah AA, Nowilaty SR, Asghar N, Al-Kharashi AS, Ghazi NG. Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema. Retina. 2015;35(3):440-8.</span>
</li>
<li id="cite_note-atchison22-23"><span class="mw-cite-backlink"><a href="#cite_ref-atchison22_23-0">↑</a></span> <span class="reference-text">Atchison EA, Wood KM, Mattox CG, Barry CN, Lum F, MacCumber MW. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry. Ophthalmology. 2018;125(5):676-82.</span>
</li>
<li id="cite_note-choi23-24"><span class="mw-cite-backlink"><a href="#cite_ref-choi23_24-0">↑</a></span> <span class="reference-text">Choi DY, Ortube MC, McCannel CA, Sarraf D, Hubschman JP, McCannel TA, et al. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib. Retina. 2011;31(6):1028-35.</span>
</li>
<li id="cite_note-freund24-25"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-freund24_25-0">25.0</a></sup> <sup><a href="#cite_ref-freund24_25-1">25.1</a></sup></span> <span class="reference-text">Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab. Ophthalmology. 2015;122(9):1802-10.</span>
</li>
<li id="cite_note-hoang25-26"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-hoang25_26-0">26.0</a></sup> <sup><a href="#cite_ref-hoang25_26-1">26.1</a></sup> <sup><a href="#cite_ref-hoang25_26-2">26.2</a></sup></span> <span class="reference-text">Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology. 2012;119(2):321-6.</span>
</li>
<li id="cite_note-kim26-27"><span class="mw-cite-backlink"><a href="#cite_ref-kim26_27-0">↑</a></span> <span class="reference-text">Kim YJ, Sung KR, Lee KS, Joe SG, Lee JY, Kim JG, et al. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure. Am J Ophthalmol. 2014;157(6):1266-71.e1.</span>
</li>
<li id="cite_note-mathalone27-28"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-mathalone27_28-0">28.0</a></sup> <sup><a href="#cite_ref-mathalone27_28-1">28.1</a></sup></span> <span class="reference-text">Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250(10):1435-40.</span>
</li>
<li id="cite_note-silva28-29"><span class="mw-cite-backlink"><a href="#cite_ref-silva28_29-0">↑</a></span> <span class="reference-text">Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, et al. The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):130-9.</span>
</li>
<li id="cite_note-bilgic29-30"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-bilgic29_30-0">30.0</a></sup> <sup><a href="#cite_ref-bilgic29_30-1">30.1</a></sup> <sup><a href="#cite_ref-bilgic29_30-2">30.2</a></sup> <sup><a href="#cite_ref-bilgic29_30-3">30.3</a></sup> <sup><a href="#cite_ref-bilgic29_30-4">30.4</a></sup></span> <span class="reference-text">Bilgic A, Kodjikian L, Chhablani J, Sudhalkar A, Trivedi M, Vasavada V, et al. Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab. J Ophthalmol. 2020;2020:7462098.</span>
</li>
<li id="cite_note-gabrielle30-31"><span class="mw-cite-backlink"><a href="#cite_ref-gabrielle30_31-0">↑</a></span> <span class="reference-text">Gabrielle PH, Nguyen V, Wolff B, Essex R, Young S, Hunt A, et al. Intraocular Pressure Changes and VEGF Inhibitor Use in Various Retinal Diseases: Long-Term Outcomes in Routine Clinical Practice: Data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2020.</span>
</li>
<li id="cite_note-cui31-32"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-cui31_32-0">32.0</a></sup> <sup><a href="#cite_ref-cui31_32-1">32.1</a></sup></span> <span class="reference-text">Cui QN, Gray IN, Yu Y, VanderBeek BL. Repeated intravitreal injections of antivascular endothelial growth factors and risk of intraocular pressure medication use. Graefes Arch Clin Exp Ophthalmol. 2019;257(9):1931-9.</span>
</li>
<li id="cite_note-eadie32-33"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-eadie32_33-0">33.0</a></sup> <sup><a href="#cite_ref-eadie32_33-1">33.1</a></sup> <sup><a href="#cite_ref-eadie32_33-2">33.2</a></sup> <sup><a href="#cite_ref-eadie32_33-3">33.3</a></sup> <sup><a href="#cite_ref-eadie32_33-4">33.4</a></sup></span> <span class="reference-text">Eadie BD, Etminan M, Carleton BC, Maberley DA, Mikelberg FS. Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery. JAMA Ophthalmol. 2017;135(4):363-8.</span>
</li>
<li id="cite_note-skalicky33-34"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-skalicky33_34-0">34.0</a></sup> <sup><a href="#cite_ref-skalicky33_34-1">34.1</a></sup></span> <span class="reference-text">Skalicky SE, Ho I, Agar A, Bank A. Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging. 2012;43(4):328-34.</span>
</li>
<li id="cite_note-du34-35"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-du34_35-0">35.0</a></sup> <sup><a href="#cite_ref-du34_35-1">35.1</a></sup> <sup><a href="#cite_ref-du34_35-2">35.2</a></sup></span> <span class="reference-text">Du J, Patrie JT, Prum BE, Netland PA, Shildkrot YE. Effects of Intravitreal Anti-VEGF Therapy on Glaucoma-like Progression in Susceptible Eyes. J Glaucoma. 2019;28(12):1035-40.</span>
</li>
<li id="cite_note-pershing35-36"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-pershing35_36-0">36.0</a></sup> <sup><a href="#cite_ref-pershing35_36-1">36.1</a></sup></span> <span class="reference-text">Pershing S, Bakri SJ, Moshfeghi DM. Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmic Surg Lasers Imaging Retina. 2013;44(5):460-4.</span>
</li>
<li id="cite_note-segal36-37"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-segal36_37-0">37.0</a></sup> <sup><a href="#cite_ref-segal36_37-1">37.1</a></sup></span> <span class="reference-text">Segal O, Ferencz JR, Cohen P, Nemet AY, Nesher R. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab. Isr Med Assoc J. 2013;15(7):352-5.</span>
</li>
<li id="cite_note-beato37-38"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-beato37_38-0">38.0</a></sup> <sup><a href="#cite_ref-beato37_38-1">38.1</a></sup></span> <span class="reference-text">Beato J, Pedrosa AC, Pinheiro-Costa J, Freitas-da-Costa P, Falcão MS, Melo A, et al. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration. Ophthalmic Res. 2016;56(1):30-4.</span>
</li>
<li id="cite_note-good38-39"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-good38_39-0">39.0</a></sup> <sup><a href="#cite_ref-good38_39-1">39.1</a></sup></span> <span class="reference-text">Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95(8):1111-4.</span>
</li>
<li id="cite_note-hoang39-40"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-hoang39_40-0">40.0</a></sup> <sup><a href="#cite_ref-hoang39_40-1">40.1</a></sup></span> <span class="reference-text">Hoang QV, Tsuang AJ, Gelman R, Mendonca LS, Della Torre KE, Jung JJ, et al. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina. 2013;33(1):179-87.</span>
</li>
<li id="cite_note-demirel40-41"><span class="mw-cite-backlink"><a href="#cite_ref-demirel40_41-0">↑</a></span> <span class="reference-text">Demirel S, Yanik O, Batioglu F, Ozmert E. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup. Int Ophthalmol. 2015;35(4):541-7.</span>
</li>
<li id="cite_note-boyer41-42"><span class="mw-cite-backlink"><a href="#cite_ref-boyer41_42-0">↑</a></span> <span class="reference-text">Boyer DS, Goldbaum M, Leys AM, Starita C. Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. Br J Ophthalmol. 2014;98(11):1543-6.</span>
</li>
<li id="cite_note-gado42-43"><span class="mw-cite-backlink"><a href="#cite_ref-gado42_43-0">↑</a></span> <span class="reference-text">Gado AS, Macky TA. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Clin Exp Ophthalmol. 2014;42(7):650-5.</span>
</li>
<li id="cite_note-g.C3.BCler43-44"><span class="mw-cite-backlink"><a href="#cite_ref-g.C3.BCler43_44-0">↑</a></span> <span class="reference-text">Güler M, Capkın M, Simşek A, Bilak S, Bilgin B, Hakim Reyhan A, et al. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber. Curr Eye Res. 2014;39(10):989-93.</span>
</li>
<li id="cite_note-rusu44-45"><span class="mw-cite-backlink"><a href="#cite_ref-rusu44_45-0">↑</a></span> <span class="reference-text">Rusu IM, Deobhakta A, Yoon D, Lee M, Slakter JS, Klancnik JM, et al. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments. Retina. 2014;34(11):2161-6.</span>
</li>
<li id="cite_note-wehrli45-46"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-wehrli45_46-0">46.0</a></sup> <sup><a href="#cite_ref-wehrli45_46-1">46.1</a></sup></span> <span class="reference-text">Wehrli SJ, Tawse K, Levin MH, Zaidi A, Pistilli M, Brucker AJ. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab. Retina. 2012;32(7):1295-301.</span>
</li>
<li id="cite_note-yoganathan46-47"><span class="mw-cite-backlink"><a href="#cite_ref-yoganathan46_47-0">↑</a></span> <span class="reference-text">Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina. 2006;26(9):994-8.</span>
</li>
<li id="cite_note-wen47-48"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-wen47_48-0">48.0</a></sup> <sup><a href="#cite_ref-wen47_48-1">48.1</a></sup></span> <span class="reference-text">Wen JC, Reina-Torres E, Sherwood JM, Challa P, Liu KC, Li G, et al. Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci. 2017;58(3):1893-8.</span>
</li>
<li id="cite_note-filek48-49"><span class="mw-cite-backlink"><a href="#cite_ref-filek48_49-0">↑</a></span> <span class="reference-text">Filek R, Hooper P, Sheidow TG, Gonder J, Chakrabarti S, Hutnik CM. Two-year analysis of changes in the optic nerve and retina following anti-VEGF treatments in diabetic macular edema patients. Clin Ophthalmol. 2019;13:1087-96.</span>
</li>
<li id="cite_note-g.C3.B3mezmariscal49-50"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-g.C3.B3mezmariscal49_50-0">50.0</a></sup> <sup><a href="#cite_ref-g.C3.B3mezmariscal49_50-1">50.1</a></sup></span> <span class="reference-text">Gómez-Mariscal M, Puerto B, Muñoz-Negrete FJ, de Juan V, Rebolleda G. Acute and chronic optic nerve head biomechanics and intraocular pressure changes in patients receiving multiple intravitreal injections of anti-VEGF. Graefes Arch Clin Exp Ophthalmol. 2019;257(10):2221-31.</span>
</li>
<li id="cite_note-wingard50-51"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-wingard50_51-0">51.0</a></sup> <sup><a href="#cite_ref-wingard50_51-1">51.1</a></sup> <sup><a href="#cite_ref-wingard50_51-2">51.2</a></sup></span> <span class="reference-text">Wingard JB, Delzell DA, Houlihan NV, Lin J, Gieser JP. Incidence of Glaucoma or Ocular Hypertension After Repeated Anti-Vascular Endothelial Growth Factor Injections for Macular Degeneration. Clin Ophthalmol. 2019;13:2563-72.</span>
</li>
<li id="cite_note-52"><span class="mw-cite-backlink"><a href="#cite_ref-52">↑</a></span> <span class="reference-text">Jeong S, Sagong M, Chang W. Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. <i>BMC Ophthalmol</i>. 2017;17:25. </span>
</li>
<li id="cite_note-53"><span class="mw-cite-backlink"><a href="#cite_ref-53">↑</a></span> <span class="reference-text">Alkin Z, Perente I, Altan C, et al.. Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab–triamcinolone acetate combination. <i>Eur J Ophthalmol</i>. 2013;23:504–509. </span>
</li>
<li id="cite_note-54"><span class="mw-cite-backlink"><a href="#cite_ref-54">↑</a></span> <span class="reference-text">Kim IK, Baek J. A case of refractory acute angle closure glaucoma after an intravitreal bevacizumab injection. <i>Korean J Ophthalmol</i>. 2020;34:493–494. </span>
</li>
<li id="cite_note-g.C3.B3mezmariscal51-55"><span class="mw-cite-backlink"><a href="#cite_ref-g.C3.B3mezmariscal51_55-0">↑</a></span> <span class="reference-text">Gómez-Mariscal M, Muñoz-Negrete FJ, Rebolleda Fernández G. Effects of Intravitreal Anti-VEGF Therapy on Glaucoma-like Progression in Susceptible Eyes. J Glaucoma. 2020;29(6):e54-e5.</span>
</li>
<li id="cite_note-:1-56"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:1_56-0">56.0</a></sup> <sup><a href="#cite_ref-:1_56-1">56.1</a></sup></span> <span class="reference-text">Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, et al.. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. <i>Invest Ophthalmol Vis Sci</i>. 2012;53:6214–6218. </span>
</li>
<li id="cite_note-57"><span class="mw-cite-backlink"><a href="#cite_ref-57">↑</a></span> <span class="reference-text">Jo Y-J, Kim W-J, Shin I-H, et al.. Longitudinal changes in retinal nerve fiber layer thickness after intravitreal anti-vascular endothelial growth factor therapy. <i>Korean J Ophthalmol</i>. 2016;30:114–120. </span>
</li>
<li id="cite_note-58"><span class="mw-cite-backlink"><a href="#cite_ref-58">↑</a></span> <span class="reference-text">Entezari M, Ramezani A, Yaseri M. Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age-related macular degeneration. <i>J Ophthalmic Vis Res</i>. 2014;9:449–452. </span>
</li>
<li id="cite_note-59"><span class="mw-cite-backlink"><a href="#cite_ref-59">↑</a></span> <span class="reference-text">Parlak M, Oner FH, Saatci AO. The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration. <i>Int Ophthalmol</i>. 2015;35:473–480.</span>
</li>
<li id="cite_note-60"><span class="mw-cite-backlink"><a href="#cite_ref-60">↑</a></span> <span class="reference-text">Valverde-Megías A, Ruiz-Calvo A, Murciano-Cespedosa A, et al.. Long-term effect of intravitreal ranibizumab therapy on retinal nerve fiber layer in eyes with exudative age-related macular degeneration. <i>Graefes Arch Clin Exp Ophthalmol</i>. 2019;257:1459–1466. </span>
</li>
<li id="cite_note-61"><span class="mw-cite-backlink"><a href="#cite_ref-61">↑</a></span> <span class="reference-text">Horsley MB, Mandava N, Maycotte MA, et al.. Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy. <i>Am J Ophthalmol</i>. 2010;150:558.e1–561.e1. </span>
</li>
<li id="cite_note-62"><span class="mw-cite-backlink"><a href="#cite_ref-62">↑</a></span> <span class="reference-text">Swaminathan SS, Kunkler AL, Quan AV, et al.. Rates of RNFL thinning in patients with suspected or confirmed glaucoma receiving unilateral intravitreal injections for exudative AMD. <i>Am J Ophthalmol</i>. 2021;226:206–216. </span>
</li>
<li id="cite_note-:2-63"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-:2_63-0">63.0</a></sup> <sup><a href="#cite_ref-:2_63-1">63.1</a></sup></span> <span class="reference-text">Soheilian M, Karimi S, Montahae T, et al.. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. <i>Graefes Arch Clin Exp Ophthalmol</i>. 2017;255:1705–1712.</span>
</li>
<li id="cite_note-bracha52-64"><span class="mw-cite-backlink"><a href="#cite_ref-bracha52_64-0">↑</a></span> <span class="reference-text">Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review. Surv Ophthalmol. 2018;63(3):281-95.</span>
</li>
<li id="cite_note-kahook53-65"><span class="mw-cite-backlink"><a href="#cite_ref-kahook53_65-0">↑</a></span> <span class="reference-text">Kahook MY, Liu L, Ruzycki P, Mandava N, Carpenter JF, Petrash JM, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina. 2010;30(6):887-92.</span>
</li>
<li id="cite_note-liu54-66"><span class="mw-cite-backlink"><a href="#cite_ref-liu54_66-0">↑</a></span> <span class="reference-text">Liu L, Ammar DA, Ross LA, Mandava N, Kahook MY, Carpenter JF. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011;52(2):1023-34.</span>
</li>
<li id="cite_note-bakri55-67"><span class="mw-cite-backlink"><a href="#cite_ref-bakri55_67-0">↑</a></span> <span class="reference-text">Bakri SJ, Ekdawi NS. Intravitreal silicone oil droplets after intravitreal drug injections. Retina. 2008;28(7):996-1001.</span>
</li>
<li id="cite_note-kahook56-68"><span class="mw-cite-backlink"><a href="#cite_ref-kahook56_68-0">↑</a></span> <span class="reference-text">Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma. 2010;19(7):437-41.</span>
</li>
<li id="cite_note-georgopoulos57-69"><span class="mw-cite-backlink"><a href="#cite_ref-georgopoulos57_69-0">↑</a></span> <span class="reference-text">Georgopoulos M, Polak K, Prager F, Prünte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol. 2009;93(4):457-62.</span>
</li>
<li id="cite_note-sniegowski58-70"><span class="mw-cite-backlink"><a href="#cite_ref-sniegowski58_70-0">↑</a></span> <span class="reference-text">Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J. 2010;4:28-9.</span>
</li>
<li id="cite_note-71"><span class="mw-cite-backlink"><a href="#cite_ref-71">↑</a></span> <span class="reference-text">Cavet ME, Vittitow JL, Impagnatiello F, et al.. Nitric oxide (NO): an emerging target for the treatment of glaucoma. <i>Invest Ophthalmol Vis Sci</i>. 2014;55:5005–5015. </span>
</li>
<li id="cite_note-72"><span class="mw-cite-backlink"><a href="#cite_ref-72">↑</a></span> <span class="reference-text">Morshedi RG, Ricca AM, Wirostko BM. Ocular hypertension following intravitreal antivascular endothelial growth factor therapy: review of the literature and possible role of nitric oxide. <i>J Glaucoma</i>. 2016;25:291–300. </span>
</li>
<li id="cite_note-73"><span class="mw-cite-backlink"><a href="#cite_ref-73">↑</a></span> <span class="reference-text">Ricca AM, Morshedi RG, Wirostko BM. High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. <i>J Ocul Pharmacol Ther</i>. 2014;31:2–10. </span>
</li>
<li id="cite_note-74"><span class="mw-cite-backlink"><a href="#cite_ref-74">↑</a></span> <span class="reference-text">Izzedine H, Rixe O, Billemont B, et al.. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. <i>Am J Kidney Dis</i>. 2007;50:203–218. </span>
</li>
<li id="cite_note-elchehab60-75"><span class="mw-cite-backlink"><a href="#cite_ref-elchehab60_75-0">↑</a></span> <span class="reference-text">El Chehab H, Le Corre A, Agard E, Ract-Madoux G, Coste O, Dot C. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. Eur J Ophthalmol. 2013;23(3):277-83.</span>
</li>
<li id="cite_note-kozobolis61-76"><span class="mw-cite-backlink"><a href="#cite_ref-kozobolis61_76-0">↑</a></span> <span class="reference-text">Kozobolis V, Panos GD, Konstantinidis A, Labiris G. Comparison of dorzolamide/timolol vs brinzolamide/brimonidine fixed combination therapy in the management of primary open-angle glaucoma. Eur J Ophthalmol. 2017;27(2):160-3.</span>
</li>
<li id="cite_note-ozcaliskan62-77"><span class="mw-cite-backlink"><a href="#cite_ref-ozcaliskan62_77-0">↑</a></span> <span class="reference-text">Ozcaliskan S, Ozturk F, Yilmazbas P, Beyazyildiz O. Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection. Int J Ophthalmol. 2015;8(3):496-500.</span>
</li>
<li id="cite_note-pece63-78"><span class="mw-cite-backlink"><a href="#cite_ref-pece63_78-0">↑</a></span> <span class="reference-text">Pece A, Allegrini D, Montesano G, Dimastrogiovanni AF. Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study. Clin Ophthalmol. 2016;10:1131-8.</span>
</li>
<li id="cite_note-theoulakis64-79"><span class="mw-cite-backlink"><a href="#cite_ref-theoulakis64_79-0">↑</a></span> <span class="reference-text">Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd. 2010;227(4):280-4.</span>
</li>
<li id="cite_note-carnotam.C3.A9ndez65-80"><span class="mw-cite-backlink">↑ <sup><a href="#cite_ref-carnotam.C3.A9ndez65_80-0">80.0</a></sup> <sup><a href="#cite_ref-carnotam.C3.A9ndez65_80-1">80.1</a></sup></span> <span class="reference-text">Carnota-Méndez P, Méndez-Vázquez C, Otero-Villar J, Saavedra-Pazos JA. Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Eur J Ophthalmol. 2014;24(5):771-7.</span>
</li>
<li id="cite_note-knecht66-81"><span class="mw-cite-backlink"><a href="#cite_ref-knecht66_81-0">↑</a></span> <span class="reference-text">Knecht PB, Michels S, Sturm V, Bosch MM, Menke MN. Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. Retina. 2009;29(8):1175-81.</span>
</li>
<li id="cite_note-pang67-82"><span class="mw-cite-backlink"><a href="#cite_ref-pang67_82-0">↑</a></span> <span class="reference-text">Pang CE, Mrejen S, Hoang QV, Sorenson JA, Freund KB. ASSOCIATION BETWEEN NEEDLE SIZE, POSTINJECTION REFLUX, AND INTRAOCULAR PRESSURE SPIKES AFTER INTRAVITREAL INJECTIONS. Retina. 2015;35(7):1401-6.</span>
</li>
<li id="cite_note-gregori68-83"><span class="mw-cite-backlink"><a href="#cite_ref-gregori68_83-0">↑</a></span> <span class="reference-text">Gregori NZ, Weiss MJ, Goldhardt R, Schiffman JC, Vega E, Mattis CA, et al. Ocular decompression with cotton swabs lowers intraocular pressure elevation after intravitreal injection. J Glaucoma. 2014;23(8):508-12.</span>
</li>
<li id="cite_note-lam69-84"><span class="mw-cite-backlink"><a href="#cite_ref-lam69_84-0">↑</a></span> <span class="reference-text">Lam J, Luttrell I, Ding L, Rezaei K, Chao JR, Chee Y, et al. Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection. Graefes Arch Clin Exp Ophthalmol. 2019;257(11):2489-94.</span>
</li>
<li id="cite_note-knip70-85"><span class="mw-cite-backlink"><a href="#cite_ref-knip70_85-0">↑</a></span> <span class="reference-text">Knip MM, Välimäki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol. 2012;90(3):254-8.</span>
</li>
<li id="cite_note-86"><span class="mw-cite-backlink"><a href="#cite_ref-86">↑</a></span> <span class="reference-text">Lode HE, Gjølberg TT, Foss S, et al.. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Sci Rep. 2019;9:18021.</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306022818
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] In‐text annotation parser time: 0.002 seconds
CPU time usage: 0.287 seconds
Real time usage: 0.302 seconds
Preprocessor visited node count: 1434/1000000
Post‐expand include size: 5002/2097152 bytes
Template argument size: 963/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 45306/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%   74.947      1 Template:Article
100.00%   74.947      1 -total
 82.38%   61.741      4 Template:Infobox_section
 23.87%   17.888      5 Template:UserLookup
  6.17%    4.626      1 Template:Review_expired
  1.83%    1.372      1 Template:Get_active_contest
  1.10%    0.823      1 Template:Infobox_begin
  1.06%    0.794      1 Template:Infobox_end
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;oldid=83217">https://eyewiki.org/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;oldid=83217</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpxjvhkmo">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Anti-VEGF_Injection_IOP_Elevations" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Anti-VEGF_Injection_IOP_Elevations" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;oldid=83217" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Anti-VEGF_Injection_IOP_Elevations&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on July 24, 2022, at 21:06.</div>
					<div>This page has been accessed 6,780 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.002},"limitreport":{"cputime":"0.287","walltime":"0.302","ppvisitednodes":{"value":1434,"limit":1000000},"postexpandincludesize":{"value":5002,"limit":2097152},"templateargumentsize":{"value":963,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":45306,"limit":5000000},"timingprofile":["100.00%   74.947      1 Template:Article","100.00%   74.947      1 -total"," 82.38%   61.741      4 Template:Infobox_section"," 23.87%   17.888      5 Template:UserLookup","  6.17%    4.626      1 Template:Review_expired","  1.83%    1.372      1 Template:Get_active_contest","  1.10%    0.823      1 Template:Infobox_begin","  1.06%    0.794      1 Template:Infobox_end"]},"cachereport":{"timestamp":"20230306022818","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":710});});</script></body>
</html>